Across TCGA pan-cancer cohorts, MTMR9LP Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MTMR9LP data layer compared with 22 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher MTMR9LP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MTMR9LP expression acts as an unfavorable survival marker.

CESC and SARC are the cancer types where MTMR9LP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.252	0.764	.006	14	view →
SARC	OS	Median	All	0.205	0.839	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: MTMR9LP tumor-vs-normal RNA expression · all MTMR9LP data types